SAB Biotherapeutics, Inc. (SABS) Insider Trading Activity

NASDAQ$3.72
Market Cap
$338.47M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
761 of 853
Rank in Industry
438 of 492

SABS Insider Trading Activity

SABS Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
–
Sells
$0
0
–

Related Transactions

About SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

Insider Activity of SAB Biotherapeutics, Inc.

Over the last 12 months, insiders at SAB Biotherapeutics, Inc. have bought $0 and sold $0 worth of SAB Biotherapeutics, Inc. stock.

On average, over the past 5 years, insiders at SAB Biotherapeutics, Inc. have bought $63,216 and sold $2,196 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 1,740 shares for transaction amount of $1,531 was made by Sullivan Eddie Joe (Chief Executive Officer) on 2023‑12‑07.

List of Insider Buy and Sell Transactions, SAB Biotherapeutics, Inc.

2023-12-07PurchaseSullivan Eddie JoeChief Executive Officer
1,740
0.0034%
$0.88
$1,531
-63.29%
2023-11-30PurchaseKing MichaelCHIEF FINANCIAL OFFICER
5,000
0.0088%
$0.90
$4,500
-65.12%
2023-11-29PurchaseReich Samuel JExecutive Chairman
11,000
0.0209%
$0.89
$9,842
-61.03%
2022-09-13PurchaseHAMILTON CHRISTINE E
10,000
0.0239%
$0.73
$7,297
+9.70%
2022-09-07PurchaseSullivan Eddie JoeCHIEF EXECUTIVE OFFICER
14,000
0.0352%
$0.74
$10,315
+14.54%
2021-10-26SaleBeyer Russell PChief Financial Officer
278
0.0005%
$7.90
$2,196
-79.14%
2021-10-14PurchaseReich Samuel JCEO and CFO
1,000
0.0023%
$10.11
$10,110
-77.38%
2021-10-13PurchaseKatz Ilan
500
0.0012%
$10.11
$5,053
-77.23%
2021-10-01PurchaseSpragens Jeffrey Gdirector
13,000
0.0299%
$10.07
$130,910
-74.98%
2021-10-01PurchaseKatz Ilan
1,000
0.0023%
$10.09
$10,090
-74.98%
2021-01-14PurchaseReich Samuel JCEO and CFO
417,200
0.9455%
$10.00
$4.17M
+3300.68%
2021-01-14PurchaseKatz Ilan
417,200
0.9455%
$10.00
$4.17M
+3300.68%
2021-01-14PurchaseBig Cypress Holdings LLCCEO and CFO
417,200
0.9455%
$10.00
$4.17M
+3300.68%
Total: 13

Insider Historical Profitability

<0.0001%
Sullivan Eddie JoeChief Executive Officer
5232304
5.7506%
$19.46M20
<0.0001%
HAMILTON CHRISTINE E
4993090
5.4877%
$18.57M10
+9.7%
Big Cypress Holdings LLCCEO and CFO
3047825
3.3498%
$11.34M10
Reich Samuel JExecutive Chairman
219001
0.2407%
$814,683.7230
<0.0001%
Spragens Jeffrey Gdirector
13000
0.0143%
$48,360.0010
<0.0001%
King MichaelCHIEF FINANCIAL OFFICER
5000
0.0055%
$18,600.0010
<0.0001%
Katz Ilan
1500
0.0016%
$5,580.0030
<0.0001%
Beyer Russell PChief Financial Officer
0
0%
$001

Historical Insider Profitability vs. Competitors

$22,707,946
106
8.30%
$303.6M
$23,426,322
55
18.10%
$363.71M
$168,352,523
35
13.58%
$310.85M
$140,595,157
34
17.93%
$343.13M
$3,668,031
23
2.05%
$341.97M
$15,509,325
19
7.10%
$326.54M
$2,469,060
18
14.45%
$304.19M
$101,822,203
13
84.03%
$362.22M
$112,952,085
11
-19.19%
$298.4M
$19,167,169
10
28.48%
$293.74M
SAB Biotherapeutics, Inc.
(SABS)
$189,648
9
-52.20%
$338.47M
$2,762,881
8
-10.76%
$330.08M
$747,947
6
10.18%
$352.13M
$58,352
4
-43.78%
$322.23M
$51,688
4
-26.18%
$381.05M
$37,067
3
-89.81%
$362.78M
$10,104,842
3
5.45%
$383.97M
$63,731
1
-19.50%
$356.44M
$950,400
1
133.43%
$324.18M

SABS Institutional Investors: Active Positions

Increased Positions32+94.12%10M+35.55%
Decreased Positions11-32.35%2M-5.86%
New Positions21New8MNew
Sold Out Positions7Sold Out2MSold Out
Total Postitions55+61.76%36M+29.68%

SABS Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Vivo Capital, Llc$43,053.0023.79%11.42M+11MNew2025-09-30
Commodore Capital Lp$16,594.009.17%4.4M+4MNew2025-09-30
Ra Capital Management, L.P.$16,594.009.17%4.4M+4MNew2025-09-30
Woodline Partners Lp$10,748.005.94%2.85M+3MNew2025-09-30
Sessa Capital Im, L.P.$8,288.004.58%2.2M+2M+379.53%2025-09-30
Bvf Inc/Il$3,516.001.94%932,697+14,871+1.62%2025-09-30
Sphera Funds Management Ltd.$2,135.001.18%566,395+566,395New2025-09-30
Vanguard Group Inc$1,379.000.76%365,753+83,382+29.53%2025-09-30
Hb Wealth Management, Llc$1,159.000.64%307,500+307,500New2025-09-30
Awm Investment Company, Inc.$754.000.42%200,000+200,000New2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.